Purple Biotech Ltd - ADR

NASDAQ:PPBT  
5.10
+0.04 (+0.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)90.01M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.3 Million
Adjusted EPS-$0.01
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Purple Biotech Ltd - ADR Stock, NASDAQ:PPBT

One Azrieli Center, Round Tower, Floor 19, Tel Aviv, Tel Aviv 670110
Israel
Phone: +972.3.933.3121
Number of Employees: 13

Description

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.